Dr. Paramjit Tappia Joins BioMark Scientific Advisory Team

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.


Vancouver, British Columbia / TheNewswire / September 19th, 2018 – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed Dr. Paramjit Tappia to its scientific advisory team.

Rashid Ahmed, President and CEO, says, “We are extremely excited to welcome Dr. Tappia into our scientific advisory team. His achievements in scientific and clinical research space will be a major asset to BioMark.  Dr. Tappia’s expertise in regulatory and clinical research brings depth and practicality as we begin to commercialize and position our technology for different oncology applications and potential linkages with other leading global institutions.”

“Biological markers are urgently needed to improve early detection, diagnosis and measuring response to treatment for cancers at large. BioMark’s technology platform could be a critically important tool for clinicians and the medical institutions”, says Dr. Tappia.

About Dr. Paramjit Tappia

Dr. Tappia over 30 years of research, including clinical and regulatory experience in clinical research with focus on nutrition in health and disease, developing novel biomarkers for human disease and understanding of subcellular and molecular mechanisms of different pathophysiological conditions. He is currently the Principal Investigator and Clinical Scientist at Asper Clinical Research Institute, St. Boniface Hospital where he manages and facilitates clinical studies for major corporations. Dr. Tappia holds Ph.D. in Biochemistry from University of Wolverhampton, U.K. and has published over 100 peer-reviewed articles in leading journals and 26 book chapter contributions. Dr. Tappia is regularly invited to present at national and international conferences. He is also actively involved in various community services across the province of Manitoba.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website https://thecse.com/.

For further information on BioMark, please Contact:

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

Tel. 604-370-0779

Email: [email protected]  

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Biomark.  Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.

Copyright (c) 2018 TheNewswire - All rights reserved.